-
Update: Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-onset Epilepsy
Published June 2018
This is an update to the 2004 American Academy of Neurology (AAN) guideline for treating new-onset focal or generalized epilepsy with second- and third-generation antiepileptic drugs (AEDs). This update reviews new evidence for efficacy, safety, and tolerability of CLB, VGB, and the 8 second-generat
-
Practice Guideline Update: Acute Treatment of Migraine in Children and Adolescents
Published August 2019
The purpose of this guideline is to systematically assess all randomized controlled trials (RCTs) that evaluated acute migraine treatments in children and adolescents. The guideline seeks to answer the following clinical question: In children and adolescents with migraine, do acute self-administered
-
Evaluation and Management of Concussion in Sports
Published March 2013
This evidence-based guideline replaces the 1997 American Academy of Neurology (AAN) practice parameter on the management of sports concussion. It reviews the evidence published since 1955 regarding the evaluation and management of sports concussion in children, adolescents, and adults. Reaffirmed o
-
Practice Guideline Update: Pharmacologic Treatment for Pediatric Migraine Prevention
Published August 2019
This guideline systematically evaluates new evidence to answer the following clinical question: In children and adolescents with migraines, do preventive pharmacologic treatments, with or without cognitive behavioral therapy (CBT), compared with placebo, reduce headache frequency? Reaffirmed on Oct
-
Practice Guideline Recommendations: Treatment of Tics in People with Tourette Syndrome and Chronic Tic Disorders
Published May 2019
The authors of the practice guideline seek to make recommendations, based on evidence identified from the systematic review, general principles of care, and related evidence, regarding the following questions: 1. In children and adults with TS or a chronic tic disorder, when should clinicians and pa
-
Immunotherapy for Guillain-Barré Syndrome
Published September 2003
This practice parameter classifies the relevant evidence on immunotherapy to provide evidence-based recommendations for the management of GBS. Reaffirmed on January 22, 2022.
-
Practice Guideline: Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder
Published February 2020
Autism spectrum disorders (ASD) are complex neurodevelopmental disorders characterized by social interaction/communication challenges and restrictive, stereotyped behavior patterns. Sleep disturbances in ASD are common. This guideline addresses the following question: In children and adolescents wit
-
Update: Vagus Nerve Stimulation for the Treatment of Epilepsy
Published August 2013
The objective of this guideline is to evaluate the evidence since the 1999 assessment regarding efficacy and safety of vagus nerve stimulation (VNS) for epilepsy, currently approved as adjunctive therapy for partial-onset seizures in patients >12 years. Reaffirmed on July 16, 2022. Endorsed by the
-
Evaluation of Children and Adolescents with Recurrent Headaches
Published August 2002
For this parameter, the authors reviewed available evidence on the evaluation of the child with recurrent headaches and made recommendations based on this evidence. Reaffirmed on July 16, 2022.
-
Evaluation, Diagnosis, and Management of Congenital Muscular Dystrophy
Published March 2015
The objective of this guideline is to delineate optimal diagnostic and therapeutic approaches to congenital muscular dystrophy (CMD) through a systematic review and analysis of the currently available literature. Reaffirmed on July 12, 2024. Co-developed with the American Association of Neuromuscu
-
Use of Serum Prolactin in Diagnosing Epileptic Seizures
Published September 2005
Based on the evidence classification scheme of the American Academy of Neurology (AAN), we propose recommendations for the use of serum PRL assay to differentiate ES from psychogenic NES. We also reviewed the usefulness of serum PRL in other settings, such as following syncope and repetitive seizure
-
Antiepileptic Drug Prophylaxis in Severe Traumatic Brain Injury
Published January 2003
The objective of this practice parameter was to review the evidence regarding antiepileptic drug (AED) prophylaxis in patients with severe traumatic brain injury (TBI) in order to make practice recommendations. Reaffirmed on September 18, 2021.
-
Comprehensive Systematic Review: Treatment of Tics in People with Tourette Syndrome and Chronic Tic Disorders
Published May 2019
This article summarizes the findings of a systematic review, conducted as the foundation of an American Academy of Neurology (AAN) practice guideline on the treatment of tics in people with Tourette syndrome (TS) and chronic tic disorders. There is evidence to support the efficacy of various medical
-
Pharmacologic Treatment of Spasticity in Children and Adolescents with Cerebral Palsy
Published January 2010
This article reviews and evaluates published evidence of the efficacy and safety of these medications in children and adolescents affected by spasticity due to CP. Reaffirmed on July 16, 2022.
-
Practice Advisory: The Utility of EEG Theta/Beta Power Ratio in ADHD Diagnosis
Published October 2016
The purpose of this practice advisory is to examine the published evidence to determine whether quantitative EEG measures have utility in the diagnosis of ADHD and to make practice recommendations based on the evidence. Reaffirmed on October 22, 2022.
-
Evaluating a First Nonfebrile Seizure in Children
Published September 2000
For this practice parameter, the authors reviewed available evidence on evaluation of the first nonfebrile seizure in children in order to make practice recommendations based on this available evidence. Last reaffirmed on October 21, 2023.
-
Temporal Lobe and Localized Neocortical Resections for Epilepsy
Published March 2003
This article addresses published evidence on the safety and efficacy of localized resective surgery, either temporal or neocortical, as treatment for uncontrolled complex partial seizures. Reaffirmed on July 16, 2022.
-
Antiseizure medication withdrawal in seizure-free patients practice advisory update
Published December 2021
This practice advisory update reviews the risks and benefits of discontinuing antiseizure medication use in seizure-free patients. According to the practice advisory, people with epilepsy who have been seizure-free (two years for adults and 1.5 to two years for children/adolescents) and stop use of
-
Update: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy
Published June 2018
Since the 2004 publications, the US Food and Drug Administration (FDA) approved 6 new third-generation AEDs and 2 older AEDs. This update reviews new evidence for efficacy of these AEDs in managing treatment-resistant (TR) focal epilepsies and generalized epilepsies (GEs) in children and adults. Re
-
Update: Corticosteroid Treatment of Duchenne Muscular Dystrophy
Published February 2016
A 2005 American Academy of Neurology (AAN) guideline on the use of corticosteroids in patients with Duchenne muscular dystrophy (DMD) recommended prednisone or deflazacort in the treatment of DMD for short-term benefit in muscle strength and function. There are currently variations in practice in co
Questions?
Email guidelines@aan.com
Call (800) 879-1960 or (612) 928-6000 (international)